Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Shanghai Henlius Biotech: Clinical Trials & FDA Approval Profile

Shanghai Henlius Biotech (Global / Institutional) sponsors 78 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 35 active protocols (18 recruiting now), 8 completed protocols, and 2 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.1%
Median Closed Enrollment vs National (145 pts)410 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Shanghai Henlius Biotech
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)78
Active Pipeline (Recruiting Now)35 (18)
Completed vs Stopped Early8 / 4 (5.1%)
Median Closed Actual Enrollment410 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals2 (2 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Shanghai Henlius Biotech
Hospital Research SiteLocationShared Protocols
Beijing Cancer HospitalBeijing, Beijing Municipality8
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality8
Cancer Hospital Chinese Academy of Medical SciencesBeijing6

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Shanghai Henlius Biotech
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07038382A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab InjectionPhase IIRECRUITING
NCT06839066A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TheraPhase IIRECRUITING
NCT06532006A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and GastriPhase IIIRECRUITING
NCT05346224A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stagePhase IIIACTIVE NOT RECRUITING
NCT05003245Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMDPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Shanghai Henlius Biotech Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI